Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$16.48
+0.1%
$15.79
$7.28
$16.88
$2.12B1.411.16 million shs1.17 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$9.18
+0.1%
$8.29
$5.37
$17.58
$599.03M1.791.25 million shs1.54 million shs
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$17.21
$14.32
$5.41
$17.61
$2.44B1.041.25 million shs2.96 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$87.56
$63.09
$23.30
$88.46
$5.45B2.231.89 million shs3.94 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.00%+4.17%+3.64%+17.54%+108.07%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
0.00%+16.56%+19.10%+36.46%+7.01%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
0.00%+21.11%+23.99%+62.21%+183.53%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+14.95%+63.18%+108.13%+143.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$16.48
+0.1%
$15.79
$7.28
$16.88
$2.12B1.411.16 million shs1.17 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$9.18
+0.1%
$8.29
$5.37
$17.58
$599.03M1.791.25 million shs1.54 million shs
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$17.21
$14.32
$5.41
$17.61
$2.44B1.041.25 million shs2.96 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$87.56
$63.09
$23.30
$88.46
$5.45B2.231.89 million shs3.94 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.00%+4.17%+3.64%+17.54%+108.07%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
0.00%+16.56%+19.10%+36.46%+7.01%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
0.00%+21.11%+23.99%+62.21%+183.53%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+14.95%+63.18%+108.13%+143.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.33
Hold$17.254.68% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.67
Reduce$8.50-7.38% Downside
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.00
Buy$22.9033.06% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.80
Moderate Buy$71.60-18.23% Downside

Current Analyst Ratings Breakdown

Latest DNA, TWST, AUPH, and TRVI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
5/22/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$80.00
5/20/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Reiterated RatingBuy$23.00
5/15/2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
DowngradeBuy (B-)Hold (C+)
5/8/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Set Price Target$30.00
(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$298.30M7.10$1.01 per share16.24$4.41 per share3.74
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M3.52N/AN/A$8.74 per share1.05
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/A$1.43 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M14.48N/AN/A$7.84 per share11.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$287.20M$2.177.5920.60N/A99.97%26.62%19.65%7/30/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest DNA, TWST, AUPH, and TRVI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.18$0.25+$0.07$0.25$76.98 million$77.71 million
5/7/2026Q1 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.2112-$1.39-$0.1789-$1.39$42.93 million$19.00 million
5/5/2026Q1 2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$0.07-$0.09-$0.02-$0.09N/AN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.08
5.55
5.01
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
5.15
5.15
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/A
24.75
24.75
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
95.76%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
18.30%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300128.60 million112.91 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64065.32 million57.03 millionOptionable
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
20141.98 million116.00 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Twist Bioscience: Huge Downside, With Little Hope Of Profits
TWST Share News Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.48 +0.02 (+0.12%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$16.47 -0.01 (-0.05%)
As of 06/18/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$9.18 +0.01 (+0.08%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$9.01 -0.17 (-1.82%)
As of 06/18/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Trevi Therapeutics stock logo

Trevi Therapeutics NASDAQ:TRVI

$17.21 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$17.41 +0.20 (+1.16%)
As of 06/18/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$87.56 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$86.40 -1.16 (-1.32%)
As of 06/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.